Author Affiliations: Department of Otolaryngology (Dr Duval) and Auditory Sciences Laboratory (Dr Daniel), McGill University, and Department of Otolaryngology–Head and Neck Surgery, Montreal Children's Hospital (Dr Daniel), Montreal, Québec, Canada.
To characterize the presentation, treatment, and outcome of neonates presenting with facial nerve palsy resulting from forceps use.
Retrospective medical chart review.
Two tertiary care pediatric hospitals.
Neonates with facial nerve palsy caused by forceps use born during the period of April 1, 1989, to April 1, 2005.
Main Outcome Measure
Resolution of facial nerve palsy.
Twenty-eight cases of facial nerve palsy caused by forceps use were identified. The palsy was classified as mild to moderate according to the House-Brackman scale. Except in 1 neonate, no treatment was initiated in any of the patients. All 21 neonates with adequate long-term follow-up recovered fully after an average period of 24 days.
Because facial nerve palsy caused by forceps use is generally mild and is associated with a favorable outcome, treatment with corticosteroids or surgery is generally not required.
We have confirmed that treatment of facial nerve paralysis secondary to forceps use is generally not necessary because most cases will resolve spontaneously. Facial nerve palsy secondary to trauma by forceps use at birth was first noticed and studied by Landouzy, who made it the subject of his doctorate thesis in 1839.1 Although his observations date from more than 150 years ago, his description of the condition was very accurate and has been confirmed by studies performed in the 20th century.
Facial nerve palsy caused by forceps use is a common occurrence, with a reported incidence of 0.8 to 7.5 cases per 1000 births overall2 and 8.8 cases per 1000 births by forceps delivery.3 Previous observations indicate that while most cases of facial nerve palsy caused by birth trauma implicate the use of forceps,3,4 up to 33% occur in spontaneous vaginal delivery without instrumentation.2 The injury is induced by the pressure of the posterior blade of the forceps or the maternal sacral promontory onto the stylomastoid foramen, or by compression of the bone overlying the vertical segment of the facial canal.5 Our objective was to characterize the presentation, treatment, and outcome of neonates presenting with facial nerve palsy caused by forceps use at 2 tertiary care pediatric hospitals.
Neonates from the Montreal Children's Hospital and Ste-Justine Hospital, Montreal, Québec, Canada, hospitalized with facial nerve palsy caused by forceps trauma and born during the period April 1, 1989, to April 1, 2005, were identified. Information gathered retrospectively from the medical charts included sex, severity of the facial nerve palsy, side affected, associated manifestations, treatment, and outcome.
A total of 28 cases of facial nerve palsy secondary to forceps use at the time of birth were identified. There were sufficient follow-up data to assess the outcome in 21 of the 28 cases. Characteristics at time of presentation of the 28 patients are as follows:
The grade of the facial nerve palsy was generally mild to moderate, with an average severity grade of II to III on the House-Brackman scale.
Four neonates presented with other associated conditions; one had a right brachial plexus injury associated with a grade III to IV left facial nerve palsy, the second had ipsilateral abducens nerve paralysis and hypotonia, the third had hepatorenal tyrosinemia, and the fourth had experienced a skull fracture. Interestingly, complete recovery was only achieved after 1 to 2 months in the first 3 patients, which is longer than the average time to complete recovery of 24 days. The neonate with a skull fracture recovered fully from his facial nerve palsy within 5 days.
With the exception of 1 neonate who received a 14-day course of oral prednisone, none received treatment targeted at the facial nerve palsy. This neonate followed a course similar to that of the others. He recovered after a period of 1 month, that is, 1 week longer than the mean recovery time.
Recovery was complete in all of the 21 cases with adequate follow-up information in the medical chart. Complete recovery was achieved in 3 days to 4 months (mean recovery period, 24 days [median, 17.5 days]). Of the 7 neonates with incomplete follow-up data, 4 achieved at least partial improvement in 5 days to 3 months, and 2 had no documented follow-up. Of particular interest, the neonate with the most severe facial nerve palsy, a grade IV on the House-Brackman scale, recovered fully within 5 days without any treatment.
There is discrepancy in the literature on the investigations and/or treatment options to be undertaken in facial palsy owing to birth trauma. Although certain authors6,7 recommend acute exploration of the nerve, most consider observation to be sufficient in uncomplicated cases.8 Arguments supporting a conservative approach include the fact that more than 90% of infants recover spontaneously9 and that, to our knowledge, no controlled study has shown an improved outcome following surgical nerve exploration and decompression. Furthermore, surgical exploration carries a high risk of iatrogenic injury.9 However, surgical exploration must be considered in infants with poor prognostic factors and in those who do not show improvement after a period of observation of 5 weeks. Factors that are considered to be associated with a poor prognosis are unilateral complete paralysis present at birth, hemotympanum, displaced fracture of the temporal bone, absence of voluntary and evoked motor unit responses in all muscles innervated by the facial nerve by 3 to 5 days of life, and no improvement of facial nerve function by 5 weeks of age.8 It is important to note that in our study none of the patients presented with poor prognostic factors, and no surgery was undertaken to explore or decompress the facial nerve.
To our knowledge, the use of corticosteroid treatment to decrease the inflammation and accelerate the recovery in neonates with facial palsy caused by forceps injury has never been addressed. In our study, all neonates with sufficient follow-up recovered fully, and the single neonate who received corticosteroids took longer than average to recover fully. Although there are limited data on corticosteroid use for this condition, our results indicate that it is not justified to expose these patients to the risks and adverse effects associated with corticosteroid treatment because the prognosis is excellent with observation alone.
Our recovery rate of 100% in patients with adequate follow-up (21 of 21) after forceps-induced facial nerve palsy is consistent with rates previously reported. In the series described by Kumari et al,10 all 16 subjects who experienced facial nerve palsy secondary to birth trauma recovered fully. In the series reported by Falco and Eriksson,3 89% of the 66 subjects with adequate follow-up recovered fully. In the series reported by Camus et al,11 only 1 of 17 subjects had a persistent weakness after 2 months and was subsequently diagnosed as having hypoplasia of the depressor anguli oris muscle. Of note, all 3 studies included newborn patients with facial nerve paralysis from various etiologies, including cases occurring subsequent to a vaginal delivery or a cesarean delivery without forceps use.
In conclusion, facial nerve palsy caused by forceps injury is a relatively common complication of forceps use and may create considerable parental distress. In our study, the reported severity was generally mild to moderate, with an average House-Brackman grade of II to III, and the prognosis was excellent, with a recovery rate of 100%, most often without treatment. This confirms that corticosteroid treatment or surgery should be withheld in neonates presenting with uncomplicated facial nerve palsy resulting from forceps trauma.
Correspondence: Sam J. Daniel, MD, MSc, FRCSC, Department of Otolaryngology, Montreal Children's Hospital, 2300 Tupper St, Montreal, H3H 1P3, QC Canada (firstname.lastname@example.org).
Submitted for Publication: August 20, 2008; accepted October 15, 2008.
Previous Presentation: This study was presented at the American Society of Pediatric Otolaryngology Annual Meeting; April 28, 2007; San Diego, California.
Author Contributions: Dr Duval had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Duval and Daniel. Acquisition of data: Duval. Analysis and interpretation of data: Duval and Daniel. Drafting of the manuscript: Duval and Daniel. Critical revision of the manuscript for important intellectual content: Duval and Daniel. Statistical analysis: Duval and Daniel. Obtained funding: Daniel. Administrative, technical, and material support: Daniel. Study supervision: Daniel.
Financial Disclosure: Dr Daniel is a speaker for and has a clinical trial contract with Alcon Research Inc.
Additional Contributions: Anthony Abela, MD, from Ste-Justine's Hospital, allowed us access to some of the patients' data presented in this article.
Thank you for submitting a comment on this article. It will be reviewed by JAMA Otolaryngology–Head & Neck Surgery editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Purchase Online Access to this article for 24 hours
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 4
Customize your page view by dragging & repositioning the boxes below.
and access these and other features:
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.